JTE 051

Drug Profile

JTE 051

Alternative Names: JTE-051

Latest Information Update: 04 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Japan Tobacco
  • Developer Akros Pharma; Japan Tobacco
  • Class Antiallergics
  • Mechanism of Action Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Hypersensitivity

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Sep 2016 Phase-II clinical trials in Rheumatoid arthritis (Adjunctive treatment) in USA (PO) (NCT02919475)
  • 30 Oct 2014 Phase-I development is ongoing in Autoimmune disorders & Hypersensitivity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top